Evidence suggesting the presence of a stem cell clone anteceding the acquisition of the JAK2-V617F mutation

Leukemia

Volumn 22, Issue 7, 2008, Pages 1472-1474

  Jamal, R ^a   Belisle C ^a   Lessard, M C ^a   Hebert J ^a,b   Roy, D C ^a,b   Levine, R ^c   Busque, L ^a,b  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; HYDROXYUREA; JANUS KINASE; METHOTREXATE; PHENYLALANINE; VALINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ANEMIA; BONE MARROW BIOPSY; CASE REPORT; CELL CLONE; CHRONIC GRAFT VERSUS HOST DISEASE; DEATH; DRUG MEGADOSE; GENE MUTATION; HOSPITAL DISCHARGE; HUMAN; HUMAN TISSUE; LETTER; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKEMOGENESIS; LEUKOCYTOSIS; MALE; PRIORITY JOURNAL; SEPTIC SHOCK; THROMBOCYTOSIS;

HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYDROXYUREA; JANUS KINASE 2; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; RECURRENCE; TRANSPLANTATION CHIMERA; TRANSPLANTATION, HOMOLOGOUS;

EID: 47549113907     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.6     Document Type: Letter

References (8)

1. Rumi E, Passamonti F, Pietra D, Della Porta MG, Arcaini L, Boggi S et al. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer 2006; 107: 2206-2211.
2. Bellanne-Chantelot C, Chaumarel I, Labopin M, Bellanger F, Barbu V, De Toma C et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 2006; 108: 346-352.
3. Kralovics R, Teo SS, Li S, Theocharides A, Buser AS, Tichelli A et al Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 2006; 108: 1377-1380.
4. Nussenzveig RH, Swierczek SI, Jelinek J, Gaikwad A, Liu E, Verstovsek S et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol 2007; 35: 32-38.
5. Campbell PJ, Baxter EJ, Beer PA, Scott LM, Bench AJ, Huntly BJ et al Mutation of JAK2 in the myeloproliferative disorders: Timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 2006; 108: 3548-3555.
6. Theocharides A, Boissinot M, Girodon F, Garand R, Teo SS, Lippert E et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 2007; 110: 375-379.
7. Levine RL, Belisle C, Wadleigh M, Zahrieh D, Lee S, Chagnon P et al X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 2006; 107: 4139-4141.
8. Brunstein CG, Hirsch BA, Miller JS, McGlennen RC, Verfaillie CM, McGlave PB et al. Non-leukemic autologous reconstitution after allogeneic bone marrow transplantation for Ph-positive chronic myelogenous leukemia: Extended remission preceding eventual relapse. Bone Marrow Transplant 2000; 26: 1173-1177.